The city of Scottsdale, Arizona, currently has 7 active clinical trials seeking participants for Alzheimer's Disease research studies.
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Recruiting
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
02/20/2025
Locations: Local Institution - 1220, Scottsdale, Arizona
Conditions: Alzheimer Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
Recruiting
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Gender:
ALL
Ages:
Between 60 years and 80 years
Trial Updated:
02/10/2025
Locations: Perseverance Research Center (PRC), Scottsdale, Arizona +1 locations
Conditions: Alzheimer Disease, Early Onset
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzheimer's Disease (Polaris-AD)
Recruiting
This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
02/05/2025
Locations: Perseverance Research Center, LLC, Scottsdale, Arizona +1 locations
Conditions: Alzheimer Disease
A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's Disease
Recruiting
The purpose of this research study is to investigate how the brain, memory, thinking, and motor behavior change both in individuals with movement and/or cognitive disorders, as well as healthy individuals. Researchers will look at measurements of memory, thinking, brain wave and muscle activity, daily functioning, and brain scans to learn more about brain disorders such as Alzheimer disease and Lewy body disease.
Gender:
ALL
Ages:
Between 50 years and 95 years
Trial Updated:
01/27/2025
Locations: Mayo Clinic Arizona, Scottsdale, Arizona
Conditions: Lewy Body Disease, Alzheimer Disease, Healthy
Phase 2b Efficacy and Safety Study of Fixed Dose Drugs Combination Type of Polypill
Recruiting
The goal of this clinical trial is to assess the clinical response to a drug combination type of polypill in patients with AD after 180 days of treatment. The anticipated study population are males and females aged 50-85 years with mild to severe Alzheimer's Disease. The duration of individual patient participation will be approximately 224 Days: up to 14 days for Screening, 180 days for study drug administration, and a final follow-up visit at 210 days. The planned study duration is 12-18 month... Read More
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
11/20/2024
Locations: Scottsdale Clinical Trials (Noah Clinical Site 017), Scottsdale, Arizona
Conditions: Alzheimer Disease
Arizona Alzheimer's Disease Research Center (ADRC)
Recruiting
The Arizona Alzheimer's Disease Research Center (ADRC) is the National Institute on Aging's (NIA's) first statewide AD Center (ADC), the only ADC in the Southwestern United States, and a leading example of statewide collaboration in biomedical research. It capitalizes on Arizona's strengths in brain imaging, genomics, computer science and biomathematics, the basic, cognitive and behavioral neurosciences, clinical, and neuropathological studies of AD, the discovery and evaluation of investigation... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/16/2024
Locations: Mayo Clinic, Scottsdale, Arizona
Conditions: Alzheimer Disease
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
Recruiting
A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
07/30/2024
Locations: Perseverance Research Center, Scottsdale, Arizona
Conditions: Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases